

Treatment Appraisal: Decision Summary

Date	20 th March 2012				
Appraisal	Collagenase (Xiapex®) for Dupuytren's contracture - appeal				
Details	The North East Treatment Advisory Group considered an appeal of their recommendation on the use of collagenase (Xiapex®) within its licensed indication for the treatment of Dupuytren's contracture as a substitute for established surgical interventions.				
Recommendation	<p>The North East Treatment Advisory Group recommends collagenase (Xiapex®) for Dupuytren's contracture limited to one joint or cord and where the flexion contracture is greater than 40° from the horizontal plane.</p> <p>The group recommends that treatment is periodically audited against the recommended treatment criteria to include assessment of baseline and post-treatment flexion contracture angle. Commissioning organisations are recommended to ensure appropriate tariff charges are applied.</p>				
Clinical evidence summary	The group had previously stated their desire to see a direct randomised comparison of collagenase with established treatment options for Dupuytren's contracture. However in the absence of such a comparison the group was grateful for the data presented by the appellant. The group was satisfied that the target patient group identified by the appellant would enhance the cost-effectiveness of treatment both through limiting the number of injections per case and reserving treatment for patients for whom surgery is more complex.				
Cost analysis summary	The group noted the high purchase cost of collagenase (Xiapex®) but acknowledged the potential for savings compared with existing surgical treatment options. The group noted data presented by the appellant which indicated that the proposed treatment criteria would apply to about 30% of current Dupuytren's contracture hand surgery patients, and that in practice patients require only about 1.1 injections per case.				
Financial impact		Estimated number of surgical cases*	Estimated number of Xiapex® cases (one-third of surgical cases)	Estimated cost of Xiapex® (mean two injections per patient)	Estimated saving against day-case palmar fasciectomy**
	Primary Care Organisation				
	NHS Durham & Darlington	148	50	£97,200	£32,400
	NHS North of Tyne	191	64	£124,416	£41,500
	NHS South of Tyne	160	54	£104,976	£35,000
	NHS Tees	126	42	£81,648	£27,200
PbR: Excluded	NHS North East	625	210	£408,240	£136,000
	* Excluding revisions and amputations. ** Adjusted to allow for surgical revision in 7% of cases.				
Further research or information	<p>This recommendation supersedes the group's previous recommendation of August 2011 (CGN-DPC-AUG11).</p> <p>An audit tool is available from Mr Richard Milner, Royal Victoria Infirmary.</p>				

Not to be used for commercial or marketing purposes